Loading
Loading
Research Overview
Only human cathelicidin antimicrobial peptide; disrupts bacterial cell membranes via electrostatic binding and membrane pore formation; also modulates innate immune responses, promotes wound healing, and inhibits certain biofilm formation.
LL-37 is a naturally occurring antimicrobial peptide that has been extensively examined in preclinical research for its potential role in host defense and immune system regulation. Derived from the human cathelicidin precursor protein (hCAP18), LL-37 consists of a short chain of amino acids and is widely studied for its activity within innate immune pathways under controlled experimental conditions. As an endogenous peptide, it is recognized for its broad-spectrum antimicrobial properties, though many aspects of its biological function remain under active scientific investigation.
Across laboratory and animal-based models, LL-37 has been explored for its potential interactions with microbial membranes, as well as its role in modulating immune responses. Research has investigated how this peptide may influence signaling pathways involved in inflammation, chemotaxis, and cellular communication. Particular attention has been given to its interaction with immune cells such as macrophages, neutrophils, and epithelial cells, along with its potential involvement in cytokine regulation and barrier defense mechanisms.
In addition to its antimicrobial activity, LL-37 has been evaluated for its potential role in tissue-related processes within experimental settings. Some preclinical findings suggest that it may contribute to wound-healing pathways, angiogenesis, and cellular proliferation, as well as responses to environmental stressors and microbial challenges.
To support experimental consistency, LL-37 has been synthesized and stabilized for laboratory use, enabling researchers to investigate its structural behavior and biological activity under controlled conditions. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, ll-37 antimicrobial peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
LL-37 Antimicrobial Peptide research is most relevant to protocols examining:
Innate immune defence and cathelicidin biology research
Antimicrobial peptide membrane disruption mechanism studies
Biofilm inhibition and chronic infection model research
Wound healing and skin barrier function investigations
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Downstream biological effects become detectable. Key biomarkers worth monitoring from this point.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
Only human cathelicidin antimicrobial peptide; disrupts bacterial cell membranes via electrostatic binding and membrane pore formation; also modulates innate immune responses, promotes wound healing, and inhibits certain biofilm formation.
| Parameter | Value |
|---|---|
| Dose range | 1–5 mg (local/systemic |
| Alt. dose 2 | dosing highly protocol-dependent) |
| Schedule | Protocol-dependent |
| Route | Subcutaneous, Topical, Inhalation |
| Half-life | ~Hours |
Community & Anecdotal Signal
Community signal is sparse and research-adjacent. LL-37 remains a fringe compound even within peptide communities, discussed primarily in immune health and antimicrobial contexts rather than as a personal use compound. Topical use for skin infections and wound healing generates the most personal reports, though the pool is thin. Injectable use reports are rarer and raise sourcing reliability questions given the technical challenges of producing quality LL-37. The antimicrobial mechanism is well understood within the community that does discuss it, and interest in the innate immunity angle is g
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
